Isatuximab

Drug Profile

Isatuximab

Alternative Names: Anti-CD38 monoclonal antibody - Sanofi; SAR-650984

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator ImmunoGen
  • Developer Sanofi
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD38 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase Unknown Acute lymphoblastic leukaemia; T cell lymphoma

Most Recent Events

  • 19 Dec 2016 Investigation in Acute lymphoblastic leukaemia in USA (IV) before December 2016
  • 19 Dec 2016 Investigation in T-cell lymphoma (T-lymphoblastic lymphoma) in USA (IV) before December 2016
  • 19 Dec 2016 Sanofi plans a phase II trial for Acute lymphoblastic leukaemia and T-cell lymphoma (Second-line therapy or greater, Monotherapy) in USA (IV) (NCT02999633)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top